贲门癌根治切除腹膜后隙温热免疫化疗临床89例疗效观察

目的　消灭贲门癌根治术中亚临床转移灶 ,减少术后复发转移 ,提高病人生存率。方法　对 176例进展期贲门癌患者在行根治切除的基础上随机分为化疗组 89例和单纯对照组 87例 ,化疗组行术中后腹膜间隙及术后腹腔内温热免疫化疗对两组患者术后复发 ,转移及 3、5年生存率进行对照分析。结果　化疗组术后腹腔内复发转移和肝转移的发生率分别为 2 4 7%和 3 7% ,明显低于对照组的 5 2 8%和 8 1% ,分别降低了 2 8 1%和 4 5 % ,差异显著 (P <0 0 5 )。 3、5年生存率分别为 63 5 %和 3 9 3 % ,明显高于对照组的 5 1 7%和 2 6 4% ,分别提高了 11 8%和 12 9% ,差异显著 (P <0 0 5 )。两组术后并发症、残胃复发和肺转移的发生率无明显差异。结论　术中、术后腹腔内温热免疫化疗是贲门癌综合治疗的一种安全有效可行方案

Retroperitoneal Hypertherimic Immunochemotherapy with High-dose Hydrocamptothecinecin after Redical Operation of Cardiac Carcinoma

Objective To eliminate sub clinical metastatic site during the excision of cardiac cancer,reduce postoperative recurrence and metastasis and increase the patient's survival rates.Methods 176 patients with cardiac cancer underwent redical resection.Of them 89 cases were treated by retroperitioneal hypertherimic immunochemotherapy with high dose hydrocamptothecinecin (treated group) and 87 cases were not treated by the chemotherapy (compared group).The 3 year and 5 year survival rates were followed up and compared in the two groups.Results Analysis succeded to demonstrate significant difference between the two grops.For treated group,however,the 3 year and 5 year survival rates (63.5% and 39.3%) increased by 11.8% and 12.9% as compared with those in the compared group ( P <0.05),and the retroperitioneal metastesis and liver recurrence rates (24.7% and 4.5%) descended by 28.1% and 3.6% as compared with those in the compared group ( P <0.05).Conclusions Retroperitoneal hypertherimic lmmunochemotherapy with high dose hydrocamptothecinecin is a effective and safe scheme during synthetical treatment to the cardiac cancer.